Pharmacology
News
Sustained response at 2 years reported for newly approved oral psoriasis agent
Long-term results with the JAK inhibitor for psoriasis show responses persist.
Conference Coverage
Pembro/chemo combo fails to improve event-free survival in head and neck cancer
Some trends favored chemoradiation plus pembrolizumab over chemoradiation alone, but KEYNOTE-412 failed to meet primary endpoint.
Conference Coverage
Heparin pretreatment may safely open arteries before STEMI cath
The “early reperfusion” associated with IRA patency at angiography “could have long-term benefit due to smaller infarct size.”
News
Clozapine may be best choice for cutting SUD risk in schizophrenia
Research on the effectiveness of pharmacotherapies for schizophrenia and comorbid substance use disorder is “very sparse.”
Conference Coverage
Cabozantinib boosts dual immunotherapy in advanced RCC
The new study suggests triplet therapy may become a new standard of care in advanced renal cell carcinoma.
News
FDA approves oral TYK2 inhibitor deucravacitinib for treating psoriasis
Approval was based on the results of two phase 3 trials of almost 1,700 adults with moderate to severe plaque psoriasis.
News
Psychiatrists’ views on psychoactive drugs clash with U.S. policy
Survey respondents viewed psilocybin and ketamine as similarly safe – and safer than methamphetamine and alprazolam.
News
DOJ: Indiana nurses allowed controlled substances during opioid recovery
“This improvement will increase access to treatment resources, enabling more nurses to complete treatment and progress toward a safe return to...
News
Hepatitis C meds linked to improved PTSD symptoms
A glecaprevir/pibrentasvir combo was associated with PTSD symptom improvement.